The obesity drug helped patients reduce their waist size by an extra two inches compared to those on Novo Nordisk’s Wegovy in ...

Eli Lilly’s (LLY) and Novo Nordisk’s (NVO) weight loss drugs went head-to-head in a weight loss study for the first time — ...

Eli Lilly said on Sunday its drug Zepbound was superior to Novo Nordisk's Wegovy across five weight-loss targets such as ...

The obesity drug helped people trim about two inches more off their waists than Wegovy in the first head-to-head study of the ...

Eli Lilly ( NYSE: LLY) on Sunday said that its drug Zepbound (tirzepatide) showed superior weight loss over Novo Nordisk's ( ...

Eli Lilly and Company's Zepbound demonstrated superior weight reduction compared to Novo Nordisk's Wegovy in a 72-week ...

In addition to eliciting greater weight loss than Novo Nordisk’s Wegovy, Eli Lilly’s Zepbound does not come at the expense of ...

Novo Nordisk shares dropped 5% in early trading on Monday after Eli Lilly released new trial data showing its weight loss ...

Participants who took tirzepatide — which is sold as Zepbound by Eli Lilly — lost an average of 50 pounds over 72 weeks.

The popular weight loss medications produced different results in patients who participated in a trial, and here’s what ...